|Cancer Stem Cell News 9.15 April 22, 2020
Scientists repurposed doxorubicin (DXR) as a targeted inhibitor rather than a broadly cytotoxic chemotherapy. Targeted DXR reduced Akt-activated β-catenin levels in chemoresistant leukemia stem cells (LSCs) and reduced LSC tumorigenic activity. [Nat Cell Biol]
CD26 chimeric antigen receptor T cells exhibited cytotoxicity against the CD26+ T-cell lymphoma cell line Karpas 299, CD26-overexpressing K562 cells and primary chronic myeloid leukemia leukemia stem cells, activated multiple effector functions in co-culture assays. [Leukemia]
Scientists demonstrated that tumor-associated macrophage-secreted CCL5 could significantly promote the migration, invasion, epithelial-mesenchymal transition of prostate cancer cells as well as the self-renewal of prostate CSCs in vitro. [Cell Death Dis]
Researchers revealed that mesenchymal stem cell (MSC) co-culture improved stemness and drug-resistance of gastric cancer (GC) cells. LncRNA histocompatibility leukocyte antigen complex P5 was induced in GC cells by MSC co-culture, contributing to stemness and drug-resistance. [Cell Death Dis]
Investigators showed that pharmacological inhibition of glutaminase eradicated glioblastoma stem-like cells, a small cell subpopulation in glioblastoma responsible for therapy resistance and tumor recurrence. [Cell Death Discov]
The authors found that ATP-binding cassette subfamily B member 5 (ABCB5) was expressed in primary glioblastoma multiforme tumors, in which its expression was significantly correlated with the CSC marker protein CD133 and with overall poor survival. [J Biol Chem]
Pharmacokinetics and dosimetry of the 211At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody were conducted using tumor xenografted mice. Sphere model analysis revealed 22.8 mGy/MBq in a tumor of 10g; the tumor-to-bone marrow and tumor-to-kidney ratios were 44.5 and 79.4, respectively. [Sci Rep]
Gefitinib surviving cells showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib could lead to propagation of CSC cell-enriched gefitinib-resistant cells. [BMC Cancer]
The author describes the emerging 3D models of glioblastoma and discusses their potential to advance our knowledge of tumor biology and CSC heterogeneity, while debating their current limitations. [Front Cell Dev Biol]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Antengene announced that it has dosed the first patient in Taiwan, China in its Phase I open-label clinical trial of ATG-019 (KPT-9274), a dual inhibitor of both PAK4 and NAMPT. [Antengene]
CytoDyn Inc. announced the treatment of the first patient with leronlimab in its Phase IIb/III trial for severe and critical COVID-19 indications. [CytoDyn, Inc.]
A survey of more than 4,000 researchers in the United States suggests that better coordination at an institutional and national level could make hundreds of thousands more tests for coronavirus available. [Nature News]
Rick Bright, one of the nation’s leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization. [STAT News]
In light of COVID-19, many conferences are being cancelled or postponed. As such:
We are suspending new event postings in our newsletters and on Twitter.
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.